sorbitol has been researched along with ci 988 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hökfelt, T; Horwell, DC; Hughes, J; Wiesenfeld-Hallin, Z; Xu, XJ | 1 |
Boden, P; Costall, B; Domeney, A; Horwell, DC; Hughes, J; Hunter, JC; Kelly, E; Pinnock, RD; Woodruff, GN | 1 |
2 other study(ies) available for sorbitol and ci 988
Article | Year |
---|---|
PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
Topics: Analgesics; Animals; Cholecystokinin; Drug Synergism; Female; Galanin; Indoles; Injections, Spinal; Kinetics; Male; Meglumine; Morphine; Naloxone; Nociceptors; Pain; Peptides; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Reflex; Sorbitol; Spinal Cord; Time Factors | 1990 |
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
Topics: Animals; Anti-Anxiety Agents; Binding, Competitive; Callitrichinae; Cell Membrane; Cerebral Cortex; Cholecystokinin; Electrophysiology; Humans; Indoles; Kinetics; Meglumine; Mice; Pancreas; Rats; Receptors, Cholecystokinin; Social Behavior; Sorbitol; Ventromedial Hypothalamic Nucleus | 1990 |